Depressive Disorder, MajorPhase 3NCT02709746
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)
A Phase 3 study testing Vortioxetine 10 mg/day, Vortioxetine 20 mg/day and Fluoxetine 20 mg/day in people with Depressive Disorder, Major, run by H. Lundbeck A/S at 124 sites in 19 countries.
Trial summary
Evaluating the efficacy of vortioxetine 10 mg/day and 20 mg/day versus placebo on depressive symptoms in adolescents (age ≥12 and ≤17 years) with a DSM-5™ (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) diagnosis of Major depressive disorder (MDD). Read more about this study
- Who is it for?
- Ages 12 to 17 years
- Conditions the study is for
- Depressive Disorder, Major
- What is being tested?
- Vortioxetine 10 mg/day, Vortioxetine 20 mg/day and Fluoxetine 20 mg/day
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 784 participants
- Where
- 124 sitesin 19 countries
- Study dates
- May 2016to 30 Jul 2019
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- The patient is a male or female, aged ≥12 and ≤17 years at Screening (patients who turn 18 years during the study will be allowed to continue in the study).
- The patient has Major depressive disorder (MDD), diagnosed according to DSM-5™.
- The patient has a Children Depression Rating Scale - Revised (CDRS-R) total score ≥45 at the Screening Visit and at the Baseline.
- The patient has a Clinical Global Impression - Severity of Illness (CGI-S) score ≥4 at the Screening Visit and at the Baseline
- The patient has provided assent to participation and parent(s)/legal representative (s) signed the Informed Consent Form.
Who cannot join
- The patient has participated in a clinical study <30 days prior to the Screening Visit.
- Other protocol defined inclusion and exclusion criteria may apply
Trial locations and contacts
124 sites in 19 countries.
124 sites in 19 countries
United States42 sites
US1009
Atlanta, Georgia
US1328
Austin, Texas
US1015
Baltimore, Maryland
US1312
Berlin, New Jersey
US1051
Cincinnati, Ohio
US1054
Cleveland, Ohio
US1385 Ericksen Research And Development
Clinton, Mississippi
US1062
Costa Mesa, California
US1064
Creve Coeur, Missouri
US1369
Dothan, Alabama
US1387
Downey, California
US1114
Escondido, California
US1217
Gainesville, Florida
US1118
Glendale, California
US1123
Imperial, California
US1261
Lake Charles, Louisiana
US1310
Little Rock, Arkansas
US1160 Renew Behavioral Health, Inc.
Long Beach, California
US1313
Marietta, Georgia
US1334
Middleburg Heights, Ohio
US1311
Naperville, Illinois
US1315
Naperville, Illinois
US1317
New York, New York
US1314
O'Fallon, Missouri
US1103
Oak Brook, Illinois
US1323
Oklahoma City, Oklahoma
US1329
Oklahoma City, Oklahoma
US1368
Orange, California
US1229
Orange City, Florida
US1308
Orem, Utah
US1370
Panorama City, California
US1320
Plano, Texas
US1222
Princeton, New Jersey
US1309
Richmond, Virginia
US1171
Rochester, New York
US1266
Saint Charles, Missouri
US1162
San Antonio, Texas
US1190
Staten Island, New York
US1333
Tucson, Arizona
US1133
Washington D.C., District of Columbia
US1386
Wichita, Kansas
US1351
Wildomar, California
Russia14 sites
RU1009
Arkhangelsk
RU1059
Engel's
RU1046
Krasnodar
RU1011
Lipetsk
RU1004
Nizhny Novgorod
RU1010
Novosibirsk
RU1012
Rostov-on-Don
RU1044
Rostov-on-Don
RU1030
Saint Petersburg
RU1013
Saratov
RU1038
Saratov
RU1057
Tomsk
RU1048
Tonnel'nyy
RU1016
Yekaterinburg
Italy7 sites
IT1075
Cagliari
IT1073
Genova
IT1029
Messina
IT1068
Naples
IT1074
Padova
IT1070
Pisa
IT1072 Osppedale Bambin gesu
Rome
Mexico7 sites
MX1014
Culiacán
MX1011
Guadalajara
MX1013
Guadalajara
MX1022
Guadalajara
MX1023
Mazatlán
MX1003
Mexico City
MX1001
Nuevo León
Poland7 sites
PL1002
Bialystok
PL1050
Gdansk
PL1068
Kielce
PL1057
Lublin
PL1052
Poznan
PL1054
Wąbrzeźno
PL1051
Wroclaw
Germany5 sites
DE1078
Freiburg im Breisgau
DE1034
Mainz
DE1077
Mannheim
DE1081
Maulbronn
DE1076
Tübingen
Serbia5 sites
RS1006 Clinic of Neurology and Psychiatry for Children and Adolescents
Belgrade
RS1010
Belgrade
RS1011
Kragujevac
RS1003
Niš
RS1007
Novi Sad
Spain5 sites
ES1041
Alcorcón
ES1044
Madrid
ES1043
Pamplona
ES1018 Hospital de Sabadell
Sabadell
ES1040
Torremolinos
South Korea4 sites
KR1035
Cheonan
UA1037
Gyeongsang
KR1032
Seoul
KR1038
Seoul
About this study
Official title: Interventional, Randomised, Double-blind, Placebo-controlled, Active Reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years, With Major Depressive Disorder (MDD)
Evaluating the efficacy of vortioxetine 10 mg/day and 20 mg/day versus placebo on depressive symptoms in adolescents (age ≥12 and ≤17 years) with a DSM-5™ (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) diagnosis of Major depressive disorder (MDD).
- Conditions
- Depressive Disorder, Major
- Being tested
- Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20 mg/day, Placebo
- Keywords
- paediatric patients
- Medical subject headings
- Depressive Disorder, Major
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Vortioxetine 10 mg/dayDrug
Also called Brintellix ®, Lu AA21004
10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
Vortioxetine 20 mg/dayDrug
Also called Brintellix ®, Lu AA21004
20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
Fluoxetine 20 mg/dayDrug
20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed
PlaceboOther
Encapsulated tablet
| Study group | Role | What they receive |
|---|---|---|
| Vortioxetine 10 mg/day | Experimental | Not described Receives: Drug: Vortioxetine 10 mg/day |
| Vortioxetine 20 mg/day | Experimental | Not described Receives: Drug: Vortioxetine 20 mg/day |
| Fluoxetine 20 mg/day, | Active comparator | Not described Receives: Drug: Fluoxetine 20 mg/day |
| Placebo | Placebo comparator | Not described Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Children Depression Rating Scale - Revised (CDRS-R) Total Score After Treatment
The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).
Measured: From Randomization to Week 8
Secondary outcomes (27)
Change in CDRS-R Total Score During Treatment (at Week 2)
The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).Children and parents answer separately. Rater judges and selects 'Best'.
Measured: At week 2
Change in CDRS-R Total Score During Treatment (at Week 4)
The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).
Measured: At week 4
Change in CDRS-R Total Score During Treatment (at Week 6)
The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).
Measured: At week 6
Change in CDRS-R Mood Score
Change in Children Depression Rating Scale - Revised (CDRS-R) Mood. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Mood is one of four subscores defined in the CDRS-R: sum of items 8, 11, 14, 15; score range 4 to 28. The highest possible score indicates the most severe measure of depression.
Measured: From randomization to Week 8
Change in CDRS-R Somatic Score
Change in Children Depression Rating Scale - Revised (CDRS-R): Somatic. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Somatic is one of four subscores defined in the CDRS-R: sum of items 4, 5, 6, 7, 16, 17; score ranges from 6 to 36. The highest possible score indicates the most severe measure of depression.
Measured: From Randomization to Week 8
Change in CDRS-R Subjective Score
Change in Children Depression Rating Scale - Revised (CDRS-R): Subjective. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Subjective is one of four subscores defined in the CDRS-R: sum of items 9, 10, 12, 13; score ranges from 4 to 28. The highest possible score indicates the most severe measure of depression.
Measured: From Randomization to Week 8
Change in CDRS-R Behaviour Score
Change in Children Depression Rating Scale - Revised (CDRS-R): Behaviour. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. behaviour is one of four subscores defined in the CDRS-R:sum of items 1, 2, 3; score ranges from 3 to 21. The highest possible score indicates the most severe measure of depression.
Measured: From Randomization to Week 8
CDRS-R Response
Children Depression Rating Scale - Response: defined as a >= 50% decrease in CDRS-R total score, calculated as (change from baseline [Randomization])/(baseline value - 17).
Measured: From Randomization to Week 8
CDRS-R Remission
Remission is defined as a CDRS-R total score <= 28.
Measured: From Randomization to Week 8
Change in General Behaviour Inventory (GBI) Depression Sub Scale Score Assessed by the Parents
Using the 10-item depression subscale, assessed by parent (PGBI-10D). Change from randomization to Week 8 in GBI Total Parent/Guardian Version Depression score. GBI is a self-report inventory with 73 items focused on mood-related behaviors including depressive, hypomanic, and biphasic symptoms. One 20-item subscale completed by parent/guardian. Symptoms rated on 4-point Likert scale from 0 (never/hardly ever) to 3 (often/almost constantly). Minimum score 0=better outcome, maximum score 60=worse outcome.
Measured: From randomization to week 8
Change General Behaviour Inventory (GBI) Depression Subscale Score Assessed by the Child
The GBI 10-item mania scale is a parent- and subject-rated scale designed to screen for manic symptoms in children and adolescents. The 10 items are rated on a scale from 0 (never or hardly ever) to 3 (very often or almost constantly). The total score ranges from 0 to 30 points, with high scores indicating greater pathology.
Measured: From randomization to Week 8
Parent Global Assessment-Global Improvement (PGA) Score
The PGA is a parent-rated variation of the CGI-I to evaluate the severity of the child's symptoms. The PGA reflects assessments of change from Baseline symptoms using a 7 point scale ranging from 1 (very much improved) to 7 (very much worse).
Measured: From Randomization to Week 8
Change in Symbol Digit Modalities Test (SDMT)
The Symbol Digit Modalities Test (SDMT) is a cognitive test designed to assess speed of performance requiring visual perception, spatial decision-making and psychomotor skills. The SDMT consists of 110 geometric symbols that the patient has to substitute with a corresponding digit in a 90-second period. Each correct digit is counted, and the total score ranges from 0 (less than normal functioning) to 110 (greater than normal functioning).
Measured: From Randomization to Week 8
Change in Clinical Global Impression Severity of Illness (CGI-S) Score
The CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients).
Measured: From Randomization to Week 8
Clinical Global Impression - Global Improvement (CGI-I) Score
The CGI-I provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). In all cases, the assessment should be made independent of whether the rater believes the improvement is drug-related or not.
Measured: From Randomization to Week 8
CGI-S Remission
Remission defined as CGI-S score of 1 or 2.
Measured: From Randomization to Week 8
Change in Children's Global Assessment Scale (CGAS) Score
The Children's Global Assessment Score (CGAS) is a rating scale which measures psychological, social and school functioning for children. The CGAS is a clinician-rated global scale to measure the lowest level of functioning for a child (4 to 16 years) during a specified time period. The CGAS contains behaviourally oriented descriptors at each anchor point that depict behaviours and life situations applicable to a child. The items range in value from 1 (most functionally impaired child) to 100 (the healthiest). A total score above 70 indicates normal function.
Measured: From Randomization to Week 8
Change in Pediatric Quality of Life Inventory (PedsQL) Visual Analogue Scales (VAS): Afraid or Scared (Anxiety) Score
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.
Measured: From Randomization to Week 8
Change in PedsQL VAS: Sad or Blue (Sadness) Score
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.
Measured: From Randomization to Week 8
Change in PedsQL VAS: Angry Score
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.
Measured: From Randomization to Week 8
Change in PedsQL VAS: Worry Score
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.
Measured: From Randomization to Week 8
Change in PedsQL VAS: Tired (Fatigue) Score
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.
Measured: From Randomization to week 8
Change in PedsQL VAS: Pain or Hurt Score
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.
Measured: From Randomization to Week 8
Change in PedsQL VAS Total Average Score
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL™ VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue, and pain using visual analogue scales. The functionality for each domain is measured on a 10cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. The total score is the average of all 6 items. A lower value represents a better outcome.
Measured: From Randomization to week 8
Change in PedsQL Emotional Distress Summary Average Score
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. The average emotional distress summary score is the mean of the anxiety, sadness, anger, and worry items. A lower value represents a better outcome.
Measured: From Randomization to week 8
Change in Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Total Scores
PQ-LES-Q total score (items 1 to 14). The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), which is used to measure quality of life in adults. The PQ LES Q consist of 15 items, item 1-14 assess the degree of satisfaction experienced by subjects in various areas of daily functioning (and item 15 allows subjects to summarize their experience in a global rating). Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good). The total score range of item 1-14 (this outcome measurement) is 14 to 70, with higher scores indicating greater satisfaction.
Measured: From Randomization to Week 8
Change in PQ-LES-Q Overall Score
PQ-LES-Q overall evaluation score (item 15). The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), which is used to measure quality of life in adults. The PQ-LES-Q consist of 15 items, item 1-14 assess the degree of satisfaction experienced by subjects in various areas of daily functioning and item 15 allows subjects to summarize their experience in a global rating (this outcome measurement). Item 15 is rated on a 5-point scale from 1 (very poor) to 5 (very good).
Measured: From Randomization to Week 8
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Mar 2016 (estimated)
- Study startMay 2016
- Primary completion2 Jul 2019
- Study completion30 Jul 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Depressive Disorder, MajorStudies of the same condition, open and under way.
- More trials run by H. Lundbeck A/SThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 784 participants (actual)
Sponsor and investigators
- Lead sponsor
- H. Lundbeck A/S
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Takeda
- Responsible party
- Sponsor
- Investigators
- Email contact via H. Lundbeck A/S, Study director, LundbeckClinicalTrials@Lundbeck.com
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02709746
- Sponsor's protocol ID
- 12710A
- Other IDs
- 2008-005354-20, 2008
- Status last verified
- Aug 2020
- First submitted
- 11 Mar 2016
- Last updated
- 19 Aug 2020
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Findling RL, DelBello MP, Zuddas A, Emslie GJ, Ettrup A, Petersen ML, Schmidt SN, Rosen M. Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study. J Am Acad Child Adolesc Psychiatry. 2022 Sep;61(9):1106-1118.e2. doi: 10.1016/j.jaac.2022.01.004. Epub 2022 Jan 13.
PubMed 35033635
Study at a glance
From the registry record, last updated by the sponsor on 19 Aug 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Interventional, Randomised, Double-blind, Placebo-controlled, Active Reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years, With Major Depressive Disorder (MDD)
- ClinicalTrials.gov ID
- NCT02709746
- Acronym / sponsor ID
- 12710A
- Conditions
- Depressive Disorder, Major
- Keywords
- paediatric patients
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 784 participants (actual)
- Lead sponsor
- H. Lundbeck A/SIndustry (pharma, biotech, devices)
- Collaborators
- Takeda
- Study start
- May 2016
- Primary completion
- 2 Jul 2019 (actual)
- Study completion
- 30 Jul 2019 (actual)
- First posted
- 16 Mar 2016 (estimated)
- Results
- Posted 19 Aug 2020
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Evaluating the efficacy of vortioxetine 10 mg/day and 20 mg/day versus placebo on depressive symptoms in adolescents (age ≥12 and ≤17 years) with a DSM-5™ (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) diagnosis of Major depressive disorder (MDD).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Vortioxetine 10 mg/day | Experimental | Drug: Vortioxetine 10 mg/day |
| Vortioxetine 20 mg/day | Experimental | Drug: Vortioxetine 20 mg/day |
| Fluoxetine 20 mg/day, | Active comparator | Drug: Fluoxetine 20 mg/day |
| Placebo | Placebo comparator | Other: Placebo |
Who may qualify
- Ages
- 12 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (5 listed)
- The patient is a male or female, aged ≥12 and ≤17 years at Screening (patients who turn 18 years during the study will be allowed to continue in the study).
- The patient has Major depressive disorder (MDD), diagnosed according to DSM-5™.
- The patient has a Children Depression Rating Scale - Revised (CDRS-R) total score ≥45 at the Screening Visit and at the Baseline.
- The patient has a Clinical Global Impression - Severity of Illness (CGI-S) score ≥4 at the Screening Visit and at the Baseline
- The patient has provided assent to participation and parent(s)/legal representative (s) signed the Informed Consent Form.
Key exclusion criteria (2 listed)
- The patient has participated in a clinical study <30 days prior to the Screening Visit.
- Other protocol defined inclusion and exclusion criteria may apply
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Vortioxetine 10 mg/dayAlso: Brintellix ®, Lu AA2100410 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed | Drug | Vortioxetine 10 mg/day |
| Vortioxetine 20 mg/dayAlso: Brintellix ®, Lu AA2100420 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed | Drug | Vortioxetine 20 mg/day |
| Fluoxetine 20 mg/day20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed | Drug | Fluoxetine 20 mg/day, |
| PlaceboEncapsulated tablet | Other | Placebo |
Primary outcome
Change in Children Depression Rating Scale - Revised (CDRS-R) Total Score After Treatment
Time frame: From Randomization to Week 8
The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).
27 secondary outcomes
Change in CDRS-R Total Score During Treatment (at Week 2)
Time frame: At week 2
Change in CDRS-R Total Score During Treatment (at Week 4)
Time frame: At week 4
Change in CDRS-R Total Score During Treatment (at Week 6)
Time frame: At week 6
Change in CDRS-R Mood Score
Time frame: From randomization to Week 8
Change in CDRS-R Somatic Score
Time frame: From Randomization to Week 8
Change in CDRS-R Subjective Score
Time frame: From Randomization to Week 8
Change in CDRS-R Behaviour Score
Time frame: From Randomization to Week 8
CDRS-R Response
Time frame: From Randomization to Week 8
CDRS-R Remission
Time frame: From Randomization to Week 8
Change in General Behaviour Inventory (GBI) Depression Sub Scale Score Assessed by the Parents
Time frame: From randomization to week 8
Change General Behaviour Inventory (GBI) Depression Subscale Score Assessed by the Child
Time frame: From randomization to Week 8
Parent Global Assessment-Global Improvement (PGA) Score
Time frame: From Randomization to Week 8
Change in Symbol Digit Modalities Test (SDMT)
Time frame: From Randomization to Week 8
Change in Clinical Global Impression Severity of Illness (CGI-S) Score
Time frame: From Randomization to Week 8
Clinical Global Impression - Global Improvement (CGI-I) Score
Time frame: From Randomization to Week 8
CGI-S Remission
Time frame: From Randomization to Week 8
Change in Children's Global Assessment Scale (CGAS) Score
Time frame: From Randomization to Week 8
Change in Pediatric Quality of Life Inventory (PedsQL) Visual Analogue Scales (VAS): Afraid or Scared (Anxiety) Score
Time frame: From Randomization to Week 8
Change in PedsQL VAS: Sad or Blue (Sadness) Score
Time frame: From Randomization to Week 8
Change in PedsQL VAS: Angry Score
Time frame: From Randomization to Week 8
Change in PedsQL VAS: Worry Score
Time frame: From Randomization to Week 8
Change in PedsQL VAS: Tired (Fatigue) Score
Time frame: From Randomization to week 8
Change in PedsQL VAS: Pain or Hurt Score
Time frame: From Randomization to Week 8
Change in PedsQL VAS Total Average Score
Time frame: From Randomization to week 8
Change in PedsQL Emotional Distress Summary Average Score
Time frame: From Randomization to week 8
Change in Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Total Scores
Time frame: From Randomization to Week 8
Change in PQ-LES-Q Overall Score
Time frame: From Randomization to Week 8
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Aug 2020.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 35033635Findling RL, DelBello MP, Zuddas A, Emslie GJ, Ettrup A, Petersen ML, Schmidt SN, Rosen M. Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study. J Am Acad Child Adolesc Psychiatry. 2022 Sep;61(9):1106-1118.e2. doi: 10.1016/j.jaac.2022.01.004. Epub 2022 Jan 13.
Related trials for Depressive Disorder, Major
RecruitingPhase 1
Open-Label Psilocybin Study in Transdiagnostic Population
Transdiagnostic, Depression - Major Depressive Disorder
Not yet recruitingPhase 2
Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies
PTSD, PTSD - Post Traumatic Stress Disorder
RecruitingPhase 2
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
Major Depressive Episode (MDE), Major Depressive Disorder (MDD)
RecruitingPhase 1
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
Depression, Major Depressive Disorder
Not yet recruiting
Acceptance and Committment Therapy Combined With Ketamine in Difficult-to-Treat Depression.
Major Depressive Disorder (MDD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Email contact via H. Lundbeck A/S study director
LundbeckClinicalTrials@Lundbeck.com
124 sites in 19 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Vortioxetine 10 mg/day, Vortioxetine 20 mg/day and Fluoxetine 20 mg/day in people with Depressive Disorder, Major, run by H. Lundbeck A/S at 124 sites in 19 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Aug 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 124 sites in United States, Russia, Italy, Mexico, Poland and 14 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 19 Aug 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Children Depression Rating Scale - Revised (CDRS-R) Total Score After Treatment (time frame: From Randomization to Week 8). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02709746, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Aug 2020.